The original goal of mRNA vaccine research was to fight cancer. After being so successful in immunizing against COVID-19, the research is refocusing on fighting cancer.
Quote: Ozlem Tureci, who co-founded the German company BioNTech with her husband, was working on a way to harness the body’s immune system to tackle tumors when they learned last year of an unknown virus infecting people in China. ... [T]he couple decided to apply the technology they’d been researching for two decades to the new threat. ...
As BioNTech’s profile has grown during the pandemic, so has its value, providing funds the company can use to pursue its original goal of developing a new tool against cancer.
“We have several different cancer vaccines based on mRNA,” said Tureci, who is BioNTech’s chief medical officer.
Asked when such a therapy might be available, Tureci said “that’s very difficult to predict in innovative development. But we expect that within only a couple of years, we will also have our vaccines [against] cancer at a place where we can offer them to people.”
Quote: The vaccines that target tumor-associated or tumor-specific antigens (TAAs or TSAs) can specifically attack and destroy malignant cells that overexpress the antigens and achieve chronic therapeutic response because of immunologic memory. Therefore, cancer vaccines offer specific, safe, and tolerable treatment compared to other immunotherapies.
Quote: Ozlem Tureci, who co-founded the German company BioNTech with her husband, was working on a way to harness the body’s immune system to tackle tumors when they learned last year of an unknown virus infecting people in China. ... [T]he couple decided to apply the technology they’d been researching for two decades to the new threat. ...
As BioNTech’s profile has grown during the pandemic, so has its value, providing funds the company can use to pursue its original goal of developing a new tool against cancer.
“We have several different cancer vaccines based on mRNA,” said Tureci, who is BioNTech’s chief medical officer.
Asked when such a therapy might be available, Tureci said “that’s very difficult to predict in innovative development. But we expect that within only a couple of years, we will also have our vaccines [against] cancer at a place where we can offer them to people.”
https://www.timesofisrael.com/scientist-behind-pfizer-vaccin...
Quote: The vaccines that target tumor-associated or tumor-specific antigens (TAAs or TSAs) can specifically attack and destroy malignant cells that overexpress the antigens and achieve chronic therapeutic response because of immunologic memory. Therefore, cancer vaccines offer specific, safe, and tolerable treatment compared to other immunotherapies.
https://molecular-cancer.biomedcentral.com/articles/10.1186/...